Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013)
Relmada Therapeutics (RLMD) posted quarterly Gross Margin of 8.86% for Q4 2013, down 505.0% year-over-year from 2.19% in Q4 2012, and down 81.99% quarter-over-quarter from 49.21% in Q2 2013.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Gross Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Gross Margin for 2 consecutive years, with 8.86% the latest figure, recorded in Q4 2013.
- In Q4 2013, Gross Margin fell 505.0% year-over-year to 8.86%; the TTM figure through Nov 2013 stood at 19.83% (changed N/A YoY), while the FY2013 annual figure was 21.31%, down 566.0% from the prior year.
- Gross Margin slipped to 8.86% in Q4 2013 per RLMD's latest filing, from 49.21% in the prior quarter.
- Across five years, Gross Margin topped out at 49.21% in Q2 2013 and bottomed at 8.86% in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Nov 30, 2013 | 8.86% |
| May 31, 2013 | 49.21% |
| Feb 28, 2013 | 20.55% |
| Nov 30, 2012 | 13.91% |
| Aug 31, 2012 | 34.13% |
| May 31, 2012 | 27.00% |